Related Experiment Video
Updated: Jun 19, 2026

07:59
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
8.9K
UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan-Related Toxicity
1Yao Liang, MD, Nagoya University Hospital, Nagoya-Shi, Japan; and Yuichi Ando, MD, PhD, Nagoya University Hospital, Nagoya-Shi, Japan.
Abstract
No abstract available in PubMed .

